HFSA 25 - CCM-D was associated with successful defibrillation and symptom improvement in patients with HFrEF at 6 months in the INTEGRA-D Trial.

Dr Nir Uriel (NewYork-Presbyterian, Columbia University Irving Medical Center, US) joins us to discuss findings from the Integra-D trial, evaluating a novel implantable device that provides both cardiac contractility modulation and defibrillation capabilities for patients with heart failure with reduced ejection fraction.

The Integra-D trial enrolled patients indicated for de novo ICD without CRT, with stage C/D heart failure on guideline-directed medical therapy and LVEF no more than 40%. This analysis presents results from the first 100 patients who received the Optimizer Integra CCM-D device, which combines two therapeutic modalities into a single implant—offering an alternative to placing separate CCM and ICD devices. The trial assessed successful device implantation, defibrillation testing, appropriate CCM delivery without ICD interaction, patient compliance with device charging, and functional status over 6 months.

Results demonstrated successful integration of both therapies with no inappropriate device interactions, high compliance, and maintenance or improvement in heart failure symptoms for the majority of patients.

Interview Questions:

1. What were the aims of the Integra-D trial?
2. What was the study design and patient population?
3. What were your key findings?
4. Can you discuss the safety profile, particularly regarding potential CCM-ICD interactions and patient compliance with device charging?
5. What are the clinical implications of these findings for device selection in patients who need both ICD protection and symptomatic heart failure management?

Recorded remotely from New York, 2025.
Editor: Jordan Rance
Videographer: David Ben-Harosh
Support: This is an independent interview produced by Radcliffe Cardiology.